Implementing PrEP in retail community pharmacies increases patient accessibility but may be difficult to incorporate without modifying workflow.
Wendy La, PharmD
Advertisement
Articles by Wendy La, PharmD
Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for previously treated HER2-positive breast cancer and gastric or gastroesophageal junction adenocarcinoma.
Ciprodex is approved for the treatment of ear infections, acute otitis media, and acute otitis externa.
Advertisement
Latest Updated Articles
Oncology Overview: Fam-trastuzumab Deruxtecan-nxki (Enhertu) for HER2-Positive Breast Cancer, Gastric AdenocarcinomaPublished: July 13th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
3
Less Common Pneumococcal Serotypes Cause More Severe Community-Acquired Pneumonia
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
